Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pigment Cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Pigment Cells. Displaying page 1 of 1.
    EudraCT Number: 2016-004110-10 Sponsor Protocol Number: 2ABC Start Date*: 2017-12-21
    Sponsor Name:Medical University of Warsaw
    Full Title: Evaluation the safety and efficacy of the treatment of scars and cutis laxa syndrome with the use of autologous (fresh and stored) stem cells isolated from adipose tissue within the project: 'The t...
    Medical condition: Scar or cutis laxa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10039581 Scar conditions and fibrosis of skin LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10011692 Cutis laxa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003229-17 Sponsor Protocol Number: Protocol1 Start Date*: 2014-10-06
    Sponsor Name:Inst of OPhthalmology, Lund University
    Full Title: To compare the effect of Eylea given every other month after three injections to treatment with a gradual extension intervals. and examine retinal function with electroretinography (ERG) in patient...
    Medical condition: To evaluate if Aflibercept given every eighth week from start after an initial loading dose in age-related macular degeneration (AMD), is as effective as dosing as "Treat and extend" where treati...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002523-28 Sponsor Protocol Number: KHAK1001 Start Date*: 2016-09-16
    Sponsor Name:Moorfields Eye Hospital
    Full Title: A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa
    Medical condition: Retinitis Pigmetosa.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004074-93 Sponsor Protocol Number: EP005 Start Date*: 2005-03-01
    Sponsor Name:EpiTan Limited
    Full Title: A Pilot, Phase II, Open, Controlled Study to Evaluate the Safety, Tolerability and Efficacy of a Subcutaneous Implant of Melanotan in Patients Suffering from Recurrent Polymorphous Light Eruption.
    Medical condition: Polymorphous Light Eruption (PMLE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001235-30 Sponsor Protocol Number: MSI-1256F-302 Start Date*: 2005-10-26
    Sponsor Name:Genaera Corporation
    Full Title: A Phase 3 Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Re...
    Medical condition: Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003426-24 Sponsor Protocol Number: GLC02-19 Start Date*: 2020-02-13
    Sponsor Name:IRCCS FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA ONLUS
    Full Title: 24-hour efficacy and tolerability of the tafluprost-timolol fixed association without preservatives in glaucomatous or ocular hypertensive patients already treated with latanoprost preserved with B...
    Medical condition: Glaucoma or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001731-20 Sponsor Protocol Number: ML29741 Start Date*: 2016-03-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A SINGLE ARM, OPEN LABEL, PHASE II, MULTICENTER STUDY TO ASSESS THE DETECTION OF THE BRAF V600 MUTATION ON cfDNA FROM PLASMA IN PATIENTS WITH ADVANCED MELANOMA
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001906-61 Sponsor Protocol Number: 20180115 Start Date*: 2020-05-18
    Sponsor Name:Amgen Inc.
    Full Title: Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy
    Medical condition: Unresectable/Metastatic Stage IIIB-IVM1d Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GR (Completed) PL (Prematurely Ended) ES (Ongoing) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000631-23 Sponsor Protocol Number: BP43963 Start Date*: 2022-11-03
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY OF MULTIPLE DOSES OF RO7247669 IN PARTICIPANTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC MELANOMA
    Medical condition: Unresectable or Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SK (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002109-20 Sponsor Protocol Number: AAV2-hRPE65v2-301 Start Date*: 2016-10-24
    Sponsor Name:Spark Therapeutics, Inc.
    Full Title: A Safety and Efficacy Study in Subjects with Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-h...
    Medical condition: Leber Congenital Amaurosis (LCA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10070667 Leber's congenital amaurosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000759-41 Sponsor Protocol Number: MO39136 Start Date*: 2018-08-30
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE II TWO COHORT STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS ATEZOLIZUMAB IN BRAFV600 WILD-TYPE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES AND COBIMETINIB PLUS ATEZOLIZU...
    Medical condition: Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) HU (Completed) ES (Completed) DE (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-015106-19 Sponsor Protocol Number: MD7110852 Start Date*: 2009-12-07
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A Phase 2b Dose-Evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
    Medical condition: Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) SE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004387-18 Sponsor Protocol Number: CO39722 Start Date*: 2018-01-09
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED AD...
    Medical condition: Metastatic BRAFV600 wild-type melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040808 Skin cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BE (Completed) HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) GR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001773-24 Sponsor Protocol Number: GO40558 Start Date*: 2019-12-05
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED M...
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002147-29 Sponsor Protocol Number: BO43328 Start Date*: 2021-11-30
    Sponsor Name:Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001250-10 Sponsor Protocol Number: LT2345-PIV-02/13 Start Date*: 2013-11-06
    Sponsor Name:Laboratoires Thea
    Full Title: Safety and Efficacy assessment of Monoprost® (unpreserved latanoprost) in comparison with Lumigan® 0.01 % and Lumigan® 0.03% UD, in patients with open angle glaucoma or ocular hypertension, stabili...
    Medical condition: glaucoma, ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) GR (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002531-15 Sponsor Protocol Number: 09/0959 Start Date*: 2016-11-14
    Sponsor Name:UCL Comprehensive Clinical Trials Unit
    Full Title: A phase II, open label, non-randomised, single centre, clinical trial of ANX776 in Healthy Volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis
    Medical condition: Glaucoma, Age-related Macular Degeneration, and Optic Neuritis.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022891 - Investigations 10047560 Visual field perimetric tests LLT
    19.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    19.0 100000004867 10021948 Infiltration intravenous injection LLT
    19.0 10022891 - Investigations 10057208 Optical coherence tomography PT
    19.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    19.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    19.0 10022891 - Investigations 10047566 Visual field tests PT
    19.0 10015919 - Eye disorders 10009034 Chronic open angle glaucoma LLT
    19.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    19.0 10015919 - Eye disorders 10006027 Borderline glaucoma PT
    19.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    19.0 10015919 - Eye disorders 10006028 Borderline glaucoma (glaucoma suspect) LLT
    19.0 10029205 - Nervous system disorders 10004571 Bilateral optic neuritis LLT
    19.0 10029205 - Nervous system disorders 10012121 Defect visual field (NOS) LLT
    19.0 100000004865 10020422 HRT LLT
    19.0 10015919 - Eye disorders 10018304 Glaucoma PT
    19.0 100000004865 10048541 Intravenous catheter management LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001198-22 Sponsor Protocol Number: ALXN2040-GA-201 Start Date*: 2021-12-02
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
    Medical condition: Geographic Atrophy (AD) secondary to Age-related Macular Degeneration (AMD).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Ongoing) CZ (Ongoing) SK (Ongoing) ES (Ongoing) IT (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:57:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA